A novel mutation in SLC1A3 causes episodic ataxia

Area of Science:

• Neurogenetics
• Molecular Neurology
• Channelopathies

Background:

• Episodic ataxias (EAs) encompass rare channelopathies with recurrent ataxia and vertigo, featuring eight subtypes.
• Genetic underpinnings are identified in four EA subtypes (EA1, EA2, EA5, EA6).
• Previous research linked EA6 exclusively to four missense mutations in the Solute Carrier Family 1 Member 3 (SLC1A3) gene.

Observation:

• Whole-exome sequencing identified a novel missense mutation, c.383T>G (p.Met128Arg), in SLC1A3 in an EA patient.
• Structural analysis suggests the p.Met128Arg mutation may disrupt the hydrophobic transmembrane environment and protein function.
• ExAC database analysis indicates loss-of-function is improbable for SLC1A3 in EA6 due to variant types.

Findings:

• The novel SLC1A3 mutation (p.Met128Arg) is associated with EA6.
• Pathogenicity assessment using tools like M-CAP score is valuable for evaluating SLC1A3 variants.
• The identified mutation is presumed to exert a gain-of-function effect, consistent with prior findings.

Implications:

• This discovery expands the known genetic spectrum of EA6.
• Understanding the gain-of-function mechanism provides insights into EA6 pathogenesis.
• Further research into SLC1A3 function and EA6 can inform diagnostic and therapeutic strategies.